For pain doctor Mark Wallace, arthritis meant his hobby of competitive swimming was becoming too painful.
“Every stroke was like an ice pick in my shoulder,” said Wallace, chief of the division of pain medicine at UC San Diego. Cortisone shots relieved the pain for about a month, and then it would return.
For philanthropist Denny Sanford, even walking was too painful. He sought relief for his arthritis with a right knee replacement, but that didn’t work well. So to treat his other knee, he looked for an alternative.
Wallace and Sanford said they found that relief with stem cells; Wallace at UC San Diego using cells from his bone marrow, and Sanford at a clinic in Germany using cells from his fat tissue. Their cases — particularly Wallace’s — illustrate how the use of stem cells to relieve joint pain is becoming an accepted part of orthopedic medicine.
With millions of baby boomers experiencing the miseries of arthritis, the need is great and growing.
Scott Wolf, CEO and Director of Research of Grace Century comments: “Regenerative medicine is gradually becoming part of mainstream healthcare and it is only a matter of time until it becomes essential. So watch our projects in this space.”
Read the rest of the article here.
Grace Century dental stem cell storage project partner Provia Laboratories LLC has begun it’s acquisition push by acquiring Vault Biobank’s dental stem cell business’ client agreements and distribution agreements. Provia will now handle storage services for Vault’s current clients, along with supplying it’s own dental stem storage product “Store-A-Tooth” to future clients acquired via Vault’s distribution channels.
Adam Houtman, Chief Executive Officer of the Vault explains, “When selecting a firm to entrust our client’s valuable samples, we chose Provia precisely because of their investment into quality, the strength of their team, and specifically the investment they’ve made into their cGMP facility. We feel confident that our client’s samples will be in the best possible hands.”
Provia offers the only cGMP dental stem cell banking solution for consumers and operates under the FDA’s current good manufacturing practice (“cGMP”) guidelines for processing human cell and tissue products.
Howard Greenman, Provia CEO, said “We are so pleased to accept the Vault’s client’s into the Provia Biobank and to continue to work with the dental office partners that the Vault has setup to inform patients of this important technology. Provia is committed to making dental stem cell banking available to families all over the world and doing so with the best technology, under the highest quality and regulatory scrutiny. As the market for dental stem cell banking continues to develop, we continue to focus on offering the best service and working with partners to do so”.
Read the full press release here.
Health companies within the digital technology sector experienced significant funding support during Q2 of 2017.
According to an article on Fierce Healthcare, data from StartUp Health has indicated that investors sunk a total of $3.8 billion into digital projects within the healthcare and medical industries during Q2. This level of investor funding has not been seen since 2011 and represents an 81% increase in comparison to the same period one year ago.
Grace Century President and Director of Research Scott Wold said “the healthcare industry is finally starting to catch-up with other industries in terms of the embracement of digital technology, and the large increase in investor dollars being pumped into healthcare projects in 2017 is a clear indication of this trend.”
Read the full Fierce Healthcare article here.
MediXall Group, Inc., the medical network arm of Grace Century Electronic Medical Records (EMR) portfolio partner Quantum, has announced that its program to recruit and enlist licensed and certified healthcare providers to its Member Network has attracted almost 1,500 registrants.
The MediXaid platform provides a B2C capability that brings together into a single, cloud-based, patent-pending virtual marketplace the consumers of healthcare products and services with providers that compete on price, location and schedule for requested products and services.
MediXall Group Chairman, Noel J. Guillama , stated, “When I envisioned the MediXaid platform I believed that healthcare would soon be moving toward the need to providing greater access, transparency and competition for the consumer and to ensuring a broader reach into a greater segment of the community for healthcare providers. Clearly, this vision has proven accurate and now even the federal government is calling for exactly what we are providing through the MediXaid platform and MediXall Group, Inc. The positive response we are seeing from the Providers we are contacting is exciting and serves to underscore that both the consumer and provider are seeing the need for a platform like MediXaid.”
Scott Wolf, President and Director of Research for Grace Century, commented “The speed of uptake from healthcare providers to the MediXall member program is very impressive. The numbers achieved to date are already 6 months ahead of MediXall member targets, and this is an excellent indicator of the future growth potential of the MediXaid platform.”
Read the full press release here
Stem cell therapy is often a “last resort” treatment for patients with end-stage heart diseases. A recent study, however, finds that the treatment could be more harmful than helpful if cardiac stem cells are involved.
Researchers found that using patients’ own cardiac stem cells to repair damaged heart tissue may not only be ineffective but that the stem cells may also develop inflammatory properties that cause further heart damage.
In the United States, around 5.7 million adults are living with heart failure. The condition occurs when the heart is no longer able to pump enough oxygen-rich blood to fulfill the body’s needs.
There is currently no cure for heart failure. In some cases, the condition can be managed through medication and lifestyle changes. For people with end-stage heart failure, however, there are limited treatment options.
Heart transplantation remains the primary treatment for end-stage heart failure, but there are not enough donor hearts to meet recipient needs. Figures from the Organ Transplantation and Procurement Network show that there are more than 3,900 patients in the U.S. waiting for a heart transplant. Last year, 3,191 heart transplants were performed.
Scott Wolf, CEO and Director of Research for Grace Century comments: “These research findings confirm the obvious fact: stem cells from the sick hearts are not good and unusable, hence, banking from a young healthy person is the only way to secure the future health.”
Read the rest of the article here.
The legal battle to get patients access to stem cell therapy in Texas is closer to reality, according to TWCNews.com latest news article.
Texas Governor Greg Abbott signed such legislation into law this week, and it means some patients will be heading into uncharted medical territory.
After Sept. 1, patients with terminal illnesses or severe chronic diseases will be allowed to access experimental stem cell treatments in Texas.
Currently, most patients who want stem cell therapy have to travel outside the United States to do it, and stem cell re-injections are only allowed here within a 24-hour window.
“This is going to protect patient health, and provide for the treatments to be done here locally at home,” said Mike Byrom, the Chief Science Officer at Austin stem cell bank BioEden.
Byrom said the new law will keep patients in the country, and will provide renewed hope for those with serious ailments.
Scott Wolf, CEO and Director of Research of Grace Century commented: ”The recognition of Stem Cells treating aliments, and acceptance in Texas is cracking the flood gates open. Get the Insurance companies on board and it lights out!“
Read the rest of the article here.
Grace Century dental stem cell storage technology partner Provia Labs have announced the launch of a valuable new resource – access to comprehensive library of stem cell material, specially allocated for stem cell researchers.
The library includes ready to ship mesenchymal stem cells (MSCs) from dental pulp (DPSC) found in human third molars or human exfoliated deciduous teeth, as well as from follicular tissue, adipose tissue, placental tissue, and umbilical cord tissue. Provia is currently developing inventory of MSCs from bone marrow, chorionic villi, and amniotic fluid.
Howard Greenman, CEO of Provia Laboratories, said “It is part of our mission to deliver quality products and services that accelerate the development of cellular therapies. Delivering high quality stem cell material to researchers fits right at the core of our mission.”
Read the full press release by clicking here.
Stem cell therapy is one step closer to becoming law in Texas, the latest state to push for passage of a patients’ “Right to Try” legislation. House Bill (HB) 810 is one of three proactive stem cell bills being considered in the Texas Legislature that would make it easier for those suffering with incurable illnesses to have access to stem cell treatments. The bill, which passed the Texas House unanimously, now heads over to the Senate.
Scott Wolf, CEO and Director of Research for Grace Century comments: “This kind of legislation, hopefully will be controlled, but moves the goal post closer for the industry. Personally, I am waiting for Insurance companies to agree to pay for storage of young healthy cells: to me that’s a no brainer for improving health down the road, while saving tons of cash.”
Read the rest of the article on WAFB
MediXall Group, Inc., who are the medical network arm of Grace Century Electronic Medical Records (EMR) portfolio partner Quantum, has confirmed that it will be offering financial products to its MediXaid® platform members.
The news, which was launched via a press release this week, reports the strategy behind offering such products to platforms members is to assist them in developing their businesses and client/patient relationships. The range of products includes options for both health care providers and their patients, and supporting financing tools will be available via TBG Holdings Corporation and its affiliate, Crossroads Capital Finance Group.
Noel Guillama, MDXL Chairman stated, “We need more transparency in healthcare, and our soon-to-be-launched health care platform, MediXaid®, will provide the price transparency consumers are demanding. The next thing that is needed is reallocation of capital to healthcare. Adding products that offer capital for growth for providers and financing services to patients, will open up new opportunities for accelerated progress. Today we have the technology to help in both cases.”
Read the full press release on Yahoo! Finance here.
It has recently been reported on Yahoo! News that MediXall Group, Inc., who are the medical network arm of Grace Century Electronic Medical Records (EMR) portfolio partner Quantum, have announced the launch of Phase 2 in the recruitment of Healthcare Providers. This has been done with the Provider Development Website, which has been designed to speed-up the enlisting of selected physician practices, diagnostic centers and medical services companies to the MediXaid Platform.
MediXall Group Chief Operating Officer, Carl Larsen, stated, “We are excited by the overwhelmingly positive response we are receiving from healthcare practices to join the MediXaid® Provider Network. We believe we have developed a strong marketing and sales program that will both facilitate the rapid development of a strong healthcare provider network in the South Florida are, plus will further serve as a foundation for expanding our reach throughout the State and nationwide.”
Grace Century President and Director of Research Scott Wolf said “Fresh Out of the box, Grace Century and Quantum’s Portfolio firm is moving forward fast. We are so excited for this firm, with Beta testing expected over the summer.”
Read the full article on Yahoo! News by clicking here.